Bioactive Peptide-Engineered Antibodies for Complement Initiation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors, such as Eculizumab, target downstream molecules and do not effectively inhibit the initiation steps of complement activation, leaving a need for inhibitors that can block the initiation of the complement system to prevent tissue damage in various disease states.
Innovation Solution
Development of bioactive peptide-bearing antibodies and fragments that are engineered to inhibit the lectin pathway of complement activation by engrafting or fusing bioactive peptides into specific regions of antibodies, such as CDRs or constant regions, to target MASP-1 and MASP-2, thereby blocking the initiation of complement activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If downstream complement inhibitors like Eculizumab are used, then complement-mediated tissue injury is reduced, but the initiation steps of complement activation are not inhibited
Solution Approach 1:
The patent uses bioactive peptides as intermediaries that specifically bind to MASP-1 and MASP-2 to block the initiation of complement activation. These peptide intermediaries prevent the formation of C3 convertase, thereby stopping the complement cascade at its source rather than blocking downstream effects.
Solution Approach 2:
The invention employs antibodies engineered with bioactive peptides that preemptively block the lectin pathway initiation by targeting MASP-1 and MASP-2 before complement activation can proceed. This preliminary blocking action prevents the formation of C3 convertase and subsequent complement cascade activation.
2Reliability
If bioactive peptides are engrafted into antibodies, then lectin pathway inhibition is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent merges bioactive peptide sequences with antibody structures through genetic engineering. The peptide sequences are integrated into the antibody's variable or constant regions, creating a unified molecule that combines the targeting capability of antibodies with the inhibitory function of bioactive peptides against MASP-1 and MASP-2.
Solution Approach 2:
The invention creates composite antibody-peptide molecules where bioactive peptide sequences are engrafted into or fused with antibody structures. This composite design allows the molecule to function both as an antibody (providing stability and targeting) and as a peptide inhibitor (blocking MASP-1/MASP-2 activity).
Data Source
AI summary
In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of CDR-H1, CDR-H2 or CDR-H3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of CDR-L1, CDR-L2 or CDR-L3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide.